Similar Adverse Event Risk for Typical, Atypical Antipsychotics

Share this content:
Similar Adverse Event Risk for Typical, Atypical Antipsychotics
Similar Adverse Event Risk for Typical, Atypical Antipsychotics

WEDNESDAY, Feb. 15, 2017 (HealthDay News) -- The risks of adverse events are similar with short-term use of typical and atypical antipsychotic medications (APMs) after cardiac surgery in seniors, according to a study published online Feb. 10 in the Journal of the American Geriatrics Society.

Dae H. Kim, M.D., M.P.H., Sc.D., from the Brigham and Women's Hospital in Boston, and colleagues conducted a retrospective cohort study involving individuals (mean age, 70 years) undergoing coronary artery bypass grafting or valve surgery (3,706 patients). Participants were either newly treated with oral atypical (2,580 patients) or typical (1,126 patients) APMs.

The researchers found that the median treatment duration was three and two days, respectively, for atypical and typical APMs, in the propensity score-matched cohort. No large differences were seen for atypical versus typical cohorts in in-hospital mortality (5.4 versus 5.3 percent; risk difference [RD], 0.1 percent; 95 percent confidence interval [CI], −2.1 to 2.3 percent), arrhythmia (2.0 versus 2.2 percent; RD, 0.0 percent; 95 percent CI, −1.4 to 1.4 percent), pneumonia (16.1 versus 14.5 percent; RD, 1.6 percent; 95 percent CI, −1.9 to 5.0 percent), and length of stay (9.9 versus 9.3 days, mean difference, 0.5 days; 95 percent CI, −1.2 to 2.2). Compared with typical APMs, use of brain imaging was more common after initiating atypical APMs (17.3 versus 12.4 percent; RD, 4.9 percent; 95 percent CI, 1.4 to 8.4).

"More research in a larger sample of individuals undergoing different surgeries is needed to confirm these findings," the authors write.

Two authors disclosed ties to the nonprofit educational organization Alosa Foundation; two authors disclosed ties to the biopharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »